RhumbLine Advisers
BCYC

RhumbLine Advisers’s Bicycle Therapeutics BCYC Stock Holding History

RhumbLine Advisers’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.3K Buy
12,571
+1,400
+13% +$8K ﹤0.01% 3564
2025
Q4 		$79.1K Buy
11,171
+7,896
+241% +$58.2K ﹤0.01% 3544
2025
Q3 		$25.3K Buy
3,275
+270
+9% +$2.04K ﹤0.01% 3749
2025
Q2 		$20.9K Buy
3,005
+1,701
+130% +$13.5K ﹤0.01% 3788
2025
Q1 		$11.1K Buy
1,304
+147
+13% +$1.73K ﹤0.01% 3821
2024
Q4 		$16.2K Buy
1,157
+57
+5% +$1.22K ﹤0.01% 3822
2024
Q3 		$24.9K Buy
1,100
+73
+7% +$1.68K ﹤0.01% 3793
2024
Q2 		$20.8K Buy
1,027
+388
+61% +$8.77K ﹤0.01% 3866
2024
Q1 		$15.9K Buy
639
+229
+56% +$4.86K ﹤0.01% 3795
2023
Q4 		$7.41K Hold
410
– – ﹤0.01% 3914
2023
Q3 		$8.23K Buy
410
+30
+8% +$686 ﹤0.01% 3902
2023
Q2 		$9.7K Buy
+380
New +$8.83K ﹤0.01% 3962

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RhumbLine Advisers's BCYC Position: Q1 2026 in Review

RhumbLine Advisers increased its Bicycle Therapeutics (BCYC) stake by 13% in Q1 2026, buying an estimated $8K and bringing the position to 12,571 shares worth $58.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3564.

RhumbLine Advisers first reported a position in BCYC in Q2 2023 and has held it in 12 quarters since. The position peaked at $79.1K in Q4 2025. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • RhumbLine Advisers held 12,571 shares of Bicycle Therapeutics worth $58.3K as of Q1 2026.
  • RhumbLine Advisers bought 1,400 Bicycle Therapeutics shares in Q1 2026, an estimated $8K.
  • Bicycle Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3564 holding.
  • RhumbLine Advisers first reported a position in Bicycle Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • RhumbLine Advisers's Bicycle Therapeutics position peaked at $79.1K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.